Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies

NCT02900651 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT02900651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02900651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
October 3, 2016
Completion date
October 9, 2024
Enrollment
139 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma